Document:

Exhibit 10.2

THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE
SECURITIES THAT MAY BE ACQUIRED PURSUANT TO THIS NOTE HAVE NOT BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE
OFFERED, SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF
WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY U.S.
PERSON, OTHER THAN DISTRIBUTORS (AS DEFINED IN REGULATION S PROMULGATED UNDER
THE SECURITIES ACT), IN THE ABSENCE OF SUCH REGISTRATION, UNLESS SUCH
TRANSACTION IS EXEMPT FROM OR NOT SUBJECT TO REGISTRATION UNDER THE SECURITIES
ACT, AND HOLDER HAS, IF REQUIRED BY THE COMPANY, DELIVERED AN OPINION OF
COUNSEL TO THAT EFFECT.  BY ACCEPTING
THIS NOTE, HOLDER REPRESENTS, AMONG OTHER THINGS, THAT IT IS AN ACCREDITED
INVESTOR (AS DEFINED IN RULE 501(a) OF THE SECURITIES ACT) AND IS NOT A U.S
PERSON, AND IS ACQUIRING THIS NOTE AND WILL ACQUIRE ANY CONVERSION SHARES (AS DEFINED
HEREIN) OUTSIDE THE U.S. AND IN ACCORDANCE WITH REGULATION S, AND WILL NOT
ENGAGE IN ANY HEDGING TRANSACTIONS WITH RESPECT TO THIS NOTE OR THE COMMON
STOCK OF THE COMPANY PRIOR TO THE EXPIRATION OF THE DISTRIBUTION COMPLIANCE
PERIOD (AS DEFINED HEREIN) EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT.  ISSUANCE OF THE CONVERSION SHARES IS
CONDITIONED UPON THE CONTINUED AVAILABILITY OF REGULATION S IN RESPECT OF
HOLDER AT TIME OF CONVERSION, OR THE AVAILABILITY TO HOLDER OF ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT IN RESPECT OF SUCH
ISSUANCE.

CONVERTIBLE
PROMISSORY NOTE

	
  US $_________

  	
   

  	
  __________, 2006

  

 

FOR VALUE
RECEIVED, Osiris Therapeutics, Inc.,
a Delaware corporation (the “Company”),
having an address of 2001 Aliceanna Street, Baltimore, MD 21231, U.S.A., hereby
promises to pay to the order of ________________ (the “Holder”),
at the offices of Holder at ________________ or such other place as may be
designated by Holder to the Company in writing, the aggregate principal amount
of __________________________ U.S. Dollars
($ _________) (the “Principal”) together with accrued and unpaid interest, upon
the terms and conditions hereinafter set forth.

1.             Payment
Terms.  The Company promises to pay
to Holder the Final Payment Amount (as hereinafter defined) on April 30, 2009 (the “Maturity Date”),
unless this Note is earlier redeemed by the Company or converted into Common
Stock (as hereinafter defined) of the Company, pursuant to Section 3
hereof, as applicable.  All accrued and
unpaid interest shall be due and payable in accordance with Section 2
hereof.  All payments hereunder shall be
made in lawful money of the United States of America. Payment shall be credited
first to the accrued and unpaid interest then due and payable and the remainder
to Principal.  “Final Payment Amount”
means an amount equal to the sum of the total unpaid Principal plus any accrued
and unpaid interest.

2.             Interest.  Interest on the outstanding portion of
Principal of this Note shall accrue at a rate of ten percent
(10%) per annum.  All
computations of interest shall be made on the basis of a 360-day year for
actual days elapsed.  All accrued
interest shall be due and payable 

 1
 

 

in cash on each Payment Date (as hereinafter defined),
the Maturity Date,  the Redemption Date
(as hereinafter defined) or Conversion Date (as hereinafter defined), as the
case may be, in each case in accordance with the terms and conditions of this
Note.  “Payment Date” means each of April
30, 2007, October 30, 2007, April 30, 2008 and October 30, 2008. Any accrued
but unpaid interest will be paid in cash at the time of conversion. If a
Payment Date, the Maturity Date, the Redemption Date or the Conversion Date, be
on a day that is not a business day, payment of any amounts due and payable on
such date shall be effected on the immediately following business day.

3.             Conversion
or Redemption of this Note.

(a)                                  Conversion.  If at any time after February 9, 2007, either
(i) the Closing Price (as defined below) of the common stock, par value USD
0.001 per share (“Common Stock”)
of the Company shall for 10 consecutive trading days following such date equal
USD 25.00 (the “Threshold Amount”)or
higher or (ii) the Holder shall make written request for conversion of this
Note upon the Company (the first to occur of (i) or (ii) after February 9,
2007, the “Conversion Date”), this
Note shall be converted in its entirety and not in part into shares of the
Common Stock.  The number of shares of
Common Stock to which Holder shall be entitled upon such conversion shall be
equal to the sum of the total unpaid principal divided by USD $18.00 (the “Note Conversion Rate”). Any accrued but
unpaid interest will be paid in cash at the time of conversion. For purposes of
this paragraph 3(a), the term „Closing Price” shall mean, as reasonably
determined by the Company, the reported closing price on the NASDAQ Global
Market.

(b)                                 Redemption.  This Note may be redeemed by the Company at
any time by payment to Holder in immediately available funds of the sum of the
total unpaid principal plus any accrued but unpaid interest.  The Company must provide written notice to
Holder not less than 30 days prior to the effective date of such redemption
(the “Redemption Date”).

(c)                                  Mechanics
of Automatic Conversion  Upon the
occurrence of either of the events specified in Section 3(a) above, this
Note shall be converted into Common Stock automatically without any further
action by Holder; provided, however, that the Company shall not be obligated to
issue a certificate or certificates evidencing the shares of Common Stock
issuable upon such conversion of this Note (“Conversion
Shares”) unless the original of this Note is delivered to the
Company, or Holder notifies the Company in writing that such original of this
Note has been lost, stolen or destroyed, and Holder executes an agreement
satisfactory to the Company to, among other things, indemnify the Company from
any loss incurred by the Company in connection with such original of this Note.  Upon surrender by Holder to the Company of
the original of this Note at the office of the Company, there shall be issued
and delivered to Holder promptly at such office and in Holder’s name as shown
on the original of this Note, a certificate or certificates for the applicable
number of Conversion Shares on the Conversion Date.  Any such certificate shall bear a conspicuous
legend similar to that set forth on page 1 of this Note (insofar as applicable)
and otherwise referring to reiterating the restrictions on transfer and other
terms hereof applicable to the Conversion Shares upon issuance.

 2
 

 

(d)                                 No
Fractional Shares.  The number of
Common Shares resulting from a conversion of this Note pursuant to Section
3(a) above shall be rounded up to the next higher integral share of Common
Stock, and no fractional shares shall be issuable by the Company upon
conversion of this Note.  Conversion of
this Note shall be deemed payment in full of this Note and this Note shall
thereupon be cancelled.

4.               The indebtedness evidenced hereby ranks pari
passu in right of payment to the indebtedness evidenced from time to time by
the other of the Offered Notes (as defined below) and to any other convertible
debt securities of the Company now or hereafter existing and so providing, and
the indebtedness evidenced hereby ranks senior in right of payment to all
classes and series of the Company’s capital stock.  By accepting this Note the Holder does
expressly consent to the aforesaid ranking in right of payment and agrees to perform, from time to time, such acts, and
to execute, acknowledge and/or deliver such other instruments, documents and
agreements, as may from time to time be requested by the Company, or as may
from time to time otherwise be reasonably requested, necessary or required, to
so confirm or provide.

5.             Representations
and Warranties of the Company.  The
Company represents and warrants to Holder as follows:

(a)                                  The
execution and delivery by the Company of this Note (i) are within the Company’s
corporate power and authority, and (ii) have been duly authorized by all
necessary corporate action.

(b)                                 This
Note is a legally binding obligation of the Company, enforceable against the
Company in accordance with the terms hereof, except to the extent that (i) such
enforceability is limited by bankruptcy, insolvency, reorganization, moratorium
or other laws relating to or affecting generally the enforcement of creditors’
rights, and (ii) the availability of the remedy of specific performance or in
injunctive or other equitable relief is subject to the discretion of the court
before which any proceeding therefore may be brought.

6.             Use
of Proceeds.  The proceeds received
by the Company from the sale of this Note shall be used by the Company for
working capital, redemption or repayment of debt or other general corporate
purposes.

7.             No
Waiver in Certain Circumstances.  No
course of dealing of Holder nor any failure or delay by Holder to exercise any
right, power or privilege under this Note shall operate as a waiver hereunder
and any single or partial exercise of any such right, power or privilege shall
not preclude any later exercise thereof or any exercise of any other right,
power or privilege hereunder.

8.             Certain
Waivers by the Company.  Except as
expressly provided otherwise in this Note, the Company and every endorser or
guarantor, if any, of this Note waive presentment, demand, notice, protest and
all other demands and notices in connection with the delivery, acceptance,
performance, default or enforcement of this Note, and assent to any extension or
postponement of the time of payment or any other indulgence, to any
substitution, exchange or release of collateral available to Holder, if any,
and to the addition or release of any other party or person primarily or
secondarily liable.

 3
 

 

9.             No
Unlawful Interest.  Notwithstanding
anything herein to the contrary, payment of any interest or other amount
hereunder shall not be required if such payment would be unlawful.  In any such event, this Note shall
automatically be deemed amended so that interest charges and all other payments
required hereunder, individually and in the aggregate, shall be equal to but
not greater than the maximum permitted by law. 
As a condition to its obligation to make any payment of interest
hereunder without withholding as may otherwise be required under applicable
U.S. tax laws, the Company may require that the Holder submit to the Company a
properly completed IRS Form W-8 or similar or successor form sufficiently
demonstrating to the reasonable satisfaction of the Company that no such
withholding is required.

10.           Representations,
Warranties and Covenants of Holder. 
By accepting this Note, Holder represents and warrants to the Company,
and agrees, as follows:

(a)                                  The
principal address of Holder is outside of the United States, and Holder is not
a U.S. Person as such term is defined and used in Regulation S.

(b)                                 At
the time the “buy” order was originated in respect of Holder’s acquisition of
this Note, Holder was outside of the U.S., and Holder is outside the U.S. as of
the date of the execution and delivery of this Note by Holder.  No offer to acquire this Note was made to
Holder or its representatives inside the United States.

(c)                                  Holder
is an “accredited investor” within the meaning of Rule 501(a) under the
Securities Act.

(d)                                 Holder
is acquiring this Note and will acquire any Conversion Shares for his/her/its
own account, not on behalf or for the account of any U.S. Person, and neither
the purchase of this Note nor the acquisition of the Conversion Shares has been
pre-arranged with a purchaser in the U.S.

(e)                                  The
Holder will make all resales of this Note and any Conversion Shares only
outside of the United States in compliance with Regulation S, or pursuant to a
registration statement under the Securities Act, or pursuant to an available
exemption from registration under the Securities Act.  Specifically, Holder will not resell this
Note or any Conversion Shares to any U.S. Person or within the United States
prior to the expiration of one year (the “Distribution
Compliance Period”) after the
closing of the offering to which this Note relates, except pursuant to
registration under the Securities Act or an exemption from registration under
the Securities Act.

(f)                                    Holder
will not engage in any hedging transactions with respect to this Note or the
Common Stock of the Company at any time prior to the expiration of the
Distribution Compliance Period, except in compliance with the Securities Act.

(g)                                 The
Company is and will be relying on the truth and accuracy of Holder’s
representations, warranties, agreements, acknowledgements and understandings as
set forth herein, in order to determine the applicability of such exemptions
and the suitability of Holder and his/her/its acquisition of the Note and
Conversion Shares upon conversion hereof.

 4
 

 

(h)                                 Holder
has been furnished with, or has acquired, copies of all of the documents filed
by the Company with the United States Securities and Exchange Commission during
the twelve months prior to the date hereof, as well as all other documents made
available by the Company for public dissemination during the same period,
including, but not limited to, press releases, and Holder has been provided all
necessary and appropriate information about the Company to make an informed
investment decision with respect to the acquisition of this Note.

(i)                                     Holder
has sufficient knowledge and experience in financial and business matters and
is capable of evaluating the risks and merits of Holder’s investment in the
Company; Holder has been provided the opportunity to make all necessary and
appropriate inquiries of the Company regarding Company’s business and
associated risks, and Company has complied with all such requests; and Holder
is able financially to bear the risk of losing Holder’s full investment in this
Note.

(j)                                     The
Note is being acquired and any Conversion Shares will be acquired in a
transaction not involving a public offering within the United States within the
meaning of the Securities Act, and Holder understands that this Note has not
been and will not be, and any Conversion Shares have not been and may not be,
registered under the Securities Act or registered or qualified under any the
securities laws of any state or other jurisdiction, are and will be “restricted
securities” and cannot be resold or otherwise transferred unless they are
registered under the Securities Act, and registered or qualified under any
other applicable securities laws, or an exemption from such registration and
qualification is available.  Prior to any
proposed transfer of this Note or any Conversion Shares, Holder shall, among
other things, give written notice to the Company of Holder’s intention to
effect such transfer, identifying the transferee and describing the manner of
the proposed transfer and, if requested by the Company, accompanied by (i)
investment representations by the transferee similar to those made by Holder in
this Section 10 and (ii) an opinion of counsel satisfactory to the Company to
the effect that the proposed transfer may be effected without registration under
the Securities Act and without registration or qualification under applicable
state or other securities laws.  Each
certificate for any Conversion Shares shall bear a legend  similar to that set forth on Page 1 of this
Note (insofar as applicable) and otherwise referring to reiterating the
restrictions on transfer and other terms hereof applicable to the Conversion
Shares upon issuance.

(k)                                  Holder
understands that no U.S. federal or state government or agency has passed on or
made any recommendation or endorsement of offering for sale or the sale of this
Note, or with respect to the Conversion Shares.

(l)                                     Holder
acknowledges that this Note is one of several similar notes (collectively the “Offered Notes”) in the aggregate principal
amount of up to $20,000,000, or at the option of the Company, a greater amount;
and that there is no restriction imposed hereby upon the Company in respect of
the incurring by the Company of additional debt or the issuance by the Company
of additional debt or equity securities, or otherwise.

 5
 

 

11.           Anti-dilution.  If the Company executes a stock split,
reverse stock split, or re-capitalization, or makes a dividend or other
distribution in cash or shares on Common Stock, or reclassifies all or part of
its outstanding Common Stock (any of the foregoing a “Dilution
Transaction”), the Note Conversion Rate and Threshold Amount
specified in Section 3(a) above shall each be equitably and proportionately
adjusted so that this Note shall be converted as of the same date as it would
have otherwise converted had such Dilution Transaction not occurred, and so
that the Holder of this Note shall upon conversion following a Dilution Event
be entitled to receive the number and kind of shares of Common Stock that such
Holder would have owned or have been entitled to receive immediately prior to
the happening of a Dilution Transaction and then, following such conversion,
subsequently subjected to the effect thereof.

12.           Registration.  Upon the request of Holder or of any holder
of any of the other Offered Notes (collectively, the “Offered
Noteholders”) following the first to occur of the conversion of this
Note and the conversion of any of the Offered Notes and the issuance of
Conversion Shares hereunder or thereunder and as defined therein, and provided
that the Company shall then be, or if not, at such time thereafter as the
Company shall become, eligible to effect the registration pursuant to the
Securities Act of the shares of Common Stock issued or issuable hereunder or
upon conversion of the other Offered Notes (collectively, the “Registrable Securities”) on Form S-3 or on another  “short form” registration statement, the
Company shall use commercially reasonable efforts to effect registration
pursuant to the Securities Act, of the Registrable Securities or the resale
thereof by the Offered Holders on Form S-3 or on another short form
registration statement.  The Company
shall have no obligation hereunder to effect any such registration at any time
which, as determined by the Company, neither Form S-3 nor any other similar
short-form registration statement is available therefor, nor shall the Company
have any obligation to maintain the effectiveness of such registration
statement for more than one year.  The
Company may delay the filing of any such registration statement as a result of
constraints or restrictions under applicable law so requiring as determined by
the Company, or suspend the effectiveness of any such registration statement
and/or require by written notice that the Offered Noteholders immediately cease
sales of shares in the event that from time to time (i) the Company files
another registration statement (other than a registration statement on Form S-8
or its successor form) under the Securities Act for a then pending or
anticipated public offering of its securities, or (ii) an event has occurred,
or the Company has entered into a transaction, which the Company determines in
good faith must be disclosed in order for the Company to comply with the public
disclosure requirements imposed on the Company under the Securities Act.  The Company shall not be required to include
any Registrable Securities in any such registration statement unless the Holder
(i) provides to the Company in a timely manner such information regarding the
Holder as is required by the Securities Act to be included in the registration
statement or provided to the Company, (ii) shall have provided to the Company
its written agreement (x) to indemnify the Company and each of its officers,
directors and agents against, and to hold the Company and its officers,
directors and agents harmless from, any losses, claims, damages, expenses or
liabilities (including reasonable attorneys fees) to which the Company or any
of its officers, directors or agents may become subject by reason of any
statement or omission in the registration statement made in reliance upon, or
in conformity with, a written statement by such Holder furnished pursuant
hereto or any failure of Holder to comply with the provisions of this Section
12, and (y) to report to the Company sales made pursuant to the registration
statement.

 6
 

 

13.           Security Interest.  The Company’s obligations under this Note and
the other Offered Notes are secured by a grant of, and the Company does hereby
grant to the Holder (and has similarly granted or is or will similarly grant to
the other Offered Noteholders in respect of the obligations under the other
Offered Notes), subject to the terms, provisions and limitations hereof, a
security interest in (the “Collateral”) all tangible and intangible assets of
the Company now existing or hereafter arising (together with products and
proceeds), other than and in any event
excluding:

(i) all tangible and
intangible assets which are the subject of any security interest previously
granted by the Company which would prohibit or conflict with a grant of a
security interest hereunder or under the other Offered Notes, and in any event
and without regard to whether or not so prohibited or conflicting, excluding
all tangible and intangible assets which are the subject of a security interest
previously granted by the Company in favor of Boston Scientific Corporation,
and

(ii) whether now or hereafter existing or
arising, all (a) leases and other contracts, (b) licenses (including licenses
to software and intellectual property), (c) rights of the Company under such
leases, other contracts and licenses, (d) property, if any, that is or becomes
the subject of such leases, other contracts or licenses, and (e) without
limiting (a) through (c), collaborative arrangements by and between the Company
and any third party and any and all interests or rights of the Company in
respect of the assets related thereto.

The
security interest granted hereby, and any corresponding lien, is and shall be
further subject and subordinate to any security interest and lien granted by
the Company in the Collateral and established at any time or from time to time
in the future as part of any financing arrangements that may be entered into by
and between the Company and any bank or financial institution, and shall rank
pari passu and shall be deemed hereby and thereby to be spread with the
security interests otherwise granted and liens established or created in the
Collateral pursuant to or as contemplated by the other Offered Notes or any other
convertible debt securities of the Company as may be issued from time to time
and which so expressly provide, and the Holder by accepting this Note does
hereby expressly consent thereto, it being the intention of the Company and the
Holder that the security interest hereby granted, and any corresponding lien
established or created, shall rank in right of priority (subject in any event
to the limits and exclusions otherwise herein provided) in respect of the
Collateral senior only to the general unsecured indebtedness and other
unsecured obligations of the Company now or hereafter existing, pari passu with
the security interests granted and liens established or created pursuant to or
as contemplated by the other Offered Notes and any other convertible debt
securities of the Company as may be issued from time to time and which so
expressly provide, and junior to any other lien created or security interest
granted by the Company.

In the event Company
fails to perform any of its repayment obligations under this Note, and such
default is continuing for a period of 10 business days after written notice
from Holder to the Company (“Default”), Holder may accelerate repayment of the
Principal plus any accrued interest and exercise, without further notice, all
rights and remedies under this Note or enforce any rights otherwise
available.  In the case of such Default,
Holder shall give the Company not less than 60 business days prior written
notice of its intended disposition of the Collateral; provided, however,
if Company cures such Default prior to expiration of such notice period,
Default will be not deemed to have occurred and Holder shall have no rights to
accelerate repayment or enforce the Collateral. 
For the purpose of enforcing any and all rights and remedies under this
Note, Holder may (i) require the Company to, upon Holder’s 

 7
 

 

reasonable request, assemble all or any part of the
Collateral as directed by the Holder and make it available to Holder during
normal business hours at the Company’s headquarters, (ii) to the extent
permitted by applicable law, enter, without breach of the peace, any premises
where any such Collateral is or may be located and, reasonably seize and remove
such Collateral from such premises, (iii) direct the Company to reasonably provide
relevant information from the Company’s books and records relating to the
Collateral, and (iv) prior to the disposition of any of the Collateral, store
or transfer the Collateral, process, repair or recondition such Collateral or
otherwise prepare it for disposition in any manner and to the extent Holder
deems reasonably appropriate. 
Notwithstanding anything to the contrary herein, the security interest
granted hereby is expressly limited to the Final Payment Amount outstanding
under this Note and Holder shall exercise the foregoing rights in such a
fashion so as to minimize disruption to Company and its business operations and
only to the extent necessary to recover such unpaid Final Payment Amount.  Holder and the Company shall work in good
faith to effectuate the intent
of the previous sentence.  The security
interest granted hereby and any corresponding lien created or established,
shall terminate and expire upon payment in full of the Final Payment Amount or
upon the occurrence of the Conversion Date, which ever first occurs, and
without further action on the part of the Company or Holder.  Holder will execute any documents or
instruments the Company may reasonably request to evidence such expiration.  All rights and remedies of the Holder
hereunder shall be exercised in a manner which recognizes rights of the other
Offered Noteholders in respect of the Collateral and in respect of the lien and
payment priority provided for hereunder.

By
acceptance of this Note, Holder acknowledges and agrees that (i) certain assets
of the Company are excluded from the security interest granted hereby, (ii) the
security interest granted to Holder pursuant hereto, and any corresponding lien
created or established, is and shall be subject and subordinate to any lien and
security interest heretofore or hereafter granted by the Company or created and
established as part of any financing arrangement that may be entered into by
and between the Company and any bank or financial institution and, subject in
any event to the limits and exclusions otherwise herein provided, such lien and
security interest shall rank senior only to the general unsecured indebtedness
and other unsecured obligations of the Company now or hereafter existing, (iii)
the Company is issuing or may issue the other Offered Notes, and in addition
thereto may also issue from time to time in the future other convertible debt
securities, and has granted or may grant in connection with the issuance of the
other Offered Notes or such other convertible debt securities, security
interests in the Collateral which may, and the lien in respect of which may,
rank pari passu in priority with the security interest granted hereby, and
Holder does hereby consent to the grant by the Company of such security
interests and the establishment and creation of such liens.  Holder shall perform, from time to time, such
acts, and shall execute, acknowledge and/or deliver such other instruments,
documents and agreements as the Company reasonably may request in order to
consummate the transactions provided for in this Note.  Without limiting the foregoing, by
accepting this Note the Holder does expressly consent to the aforesaid ranking
in respect of lien priority and subordination and agrees to perform, from time to time, such acts, and
to execute, acknowledge and/or deliver such instruments, documents and
agreements, as may from time to time be requested by the Company, or as may
from time to time otherwise be reasonably requested, necessary or required, to
so confirm or provide.

14.           Miscellaneous.  No modification, rescission, waiver,
forbearance, release or amendment of any provision of this Note shall be made,
except by a written agreement duly executed by each of the Company and Holder.  This Note may not be conveyed, assigned or 

 8
 

 

transferred by Holder without the prior written
consent of the Company.  Any permitted
subsequent Holder of this Note shall be deemed, by accepting this Note, to have
made and reaffirmed to the Company each and every of the acknowledgements,
consents, agreements, representations, warranties and covenants of the original
Holder hereof.  All notices hereunder
shall be in writing and be deemed given if personally delivered, sent by
overnight courier (provided proof of delivery is received) or sent by telecopy
(provided a confirmation of transmission is received) at the addresses of the
respective parties set forth in the initial paragraph of this Note or such
other address as either party shall notify the other of from time to time.  The Company hereby submits to personal
jurisdiction in the State of Maryland, consents to the jurisdiction of any
competent state or federal district court sitting in the County of Montgomery
County, Maryland, and waives any and all rights to raise lack of personal
jurisdiction as a defense in any action, suit or proceeding in connection with
this Note or any related matter.  This
Note shall be governed by, and construed and interpreted in accordance with,
the laws of the State of Maryland, without reference to conflicts of law
provisions of such state.

IN
WITNESS WHEREOF, the undersigned have caused this Note to be executed and
delivered by a duly authorized officer as of the date first above written.

	
  

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Osiris Therapeutics, Inc.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ACCEPTED as of the date first above written:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Holder:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 9Exhibit
10.3

Freidli Corporate
Finance Inc.

Freigutstrasse 5

8002 Zürich

Switzerland

October 30, 2006

Osiris
Therapeutics, Inc.

2001
Aliceanna Street

Baltimore, Maryland 
21231-3043

Re:          $20,000,000 Convertible Note
Offering

This letter is written in
connection with the proposal of Friedli Corporate Finance, Inc., a Belize
corporation (“FCF”), to undertake on behalf of Osiris Therapeutics, Inc., a
Delaware corporation (“Osiris”), an offering of up to $20,000,000 in
convertible promissory notes (the “Notes”) of Osiris (the “Offering”).  The Notes are, subject to certain conditions,
convertible into shares of the Common Stock, par value $0.001 per share (the “Common
Stock”), of Osiris.  The purpose of this
letter is to set forth certain of the understandings between FCF and Osiris in
connection with the Offering.  Additional
understandings with regard to the arrangement between Osiris and FCF in respect
of the Offering may be the subject of other and additional letters and
agreements by and between the parties.

Osiris and FCF each
understand that the Offering is to be undertaken in compliance with Regulation
S (“Regulation S”) under the United States Securities Act of 1933, as amended
(the “Act”), and also in compliance with the requirements of Regulation D under
the Act.  To that end, FCF does hereby
represent, warrant, covenant and agree, in connection with the Offering, as
follows:

1.             Neither FCF nor any of its affiliates, nor any person
acting on its behalf, have engaged or will engage in any “directed selling
efforts” (as such term is defined in Regulation S) in the United States with
respect to the offering of the Notes, and they have complied and will comply
with the offering restriction requirements of Regulation S in connection with
the Offering.

2.             FCF acknowledges that neither the Notes nor the shares
of Common Stock issuable upon conversion thereof have been, and the Notes will
not be, and the shares of Common Stock issuable upon conversion thereof may not
be, registered under the Act, and that, prior to the expiration of one year
after the closing of the Offering (the “Distribution Compliance Period”),
neither the Notes nor the shares of Common Stock issued upon conversion thereof
may 

 

be offered or sold within the United States, or for
the account or benefit of, any U.S. Person (as defined in Regulation S), except
in accordance with the provisions of Rule 903 or 904 of Regulation S under the
Act, or pursuant to an exemption from the registration requirements of the Act,
or, in the case of any shares of Common Stock issued upon conversion of the
Notes, unless registered pursuant to the Act.

3.             At or prior to the confirmation of sale of any of the
Notes, FCF will have sent to each distributor, dealer or other person receiving
any sort of selling concession, fee or other remuneration in connection with
the purchase or placement of any of the Notes, and to each purchaser of the
Notes in the Offering, a confirmation or notice to substantially the effect as
that which is set forth as the legend on the cover page of the form of Note.

4.             FCF will not engage in hedging transactions with respect
to offers and sales of the Notes or with respect to any shares of Common Stock
of Osiris, during the Distribution Compliance Period, and any and all offering
materials and documents used by FCF in connection with the Offering shall
disclose, in a legend or legends prominently placed, that neither the Notes nor
the shares of Common Stock issued or issuable upon conversion thereof are
registered under the Act, and that neither the Notes nor such shares of Common
Stock can be sold in the United States or to any U.S. Person other than a
distributor during the Distribution Compliance Period, unless they are
registered or unless an exemption from registration is available in respect of
such sale.

5.             To the best of the knowledge of FCF, any and all Notes
placed by or on behalf of FCF in connection with or in furtherance of the
Offering, will be placed to individuals or entities resident of, and if an
entity, organized under the laws of, a jurisdiction other than the United
States, and which or whom are in each case “accredited investors” as defined in
Rule 501(a) of the Act, or “qualified institutional buyers” within the meaning
of Rule 144A of the Act.

6.             FCF will undertake and consummate the Offering of the
Notes, including the issuance of any shares of Common Stock upon the conversion
thereof, in compliance with the applicable securities and other laws, rules and
regulations of the jurisdiction in which such offers and sales occur, including
without limitation, those of the country of Switzerland.

And Osiris does hereby
represent, warrant, covenant and agree, in connection with the Offering, as
follows:

7.             Assuming the accuracy of FCF’s statement as included in
paragraph 1 above, neither Osiris nor any of its affiliates, nor any person
acting on its behalf, has engaged or will engage in any “directed selling
efforts” (as such term is defined in Regulation S) with respect to the Offering
of the Notes, and Osiris has complied and will comply with the offering
restrictions requirements of Regulation S in connection with the Offering.

8.             Osiris will not consent to or otherwise permit or allow,
and will refuse, any transfer of any of the Notes, or of any shares of Common
Stock as may be issued from time to time upon conversion thereof, in either
case, not made in compliance with Regulation S, pursuant to registration under
the Act, or pursuant to an available exemption from such registration.

 2
 

 

Each of the parties to
this letter acknowledges that the other will be relying upon the truth and
accuracy of the other’s representations, warranties, agreements and
acknowledgements as set forth herein, in order to determine the applicability
of exemptions from the registration provisions of the Act with respect to the
issuance and sale of the Notes in the Offering, and in connection with the
issuance of the shares of Common Stock of Osiris issued upon the conversion of
the Notes, and each does hereby agree to indemnify and to hold the other
harmless from and against any and all claims, demands or liabilities as may
result or arise from any breach therof.

Please acknowledge your
agreement with the foregoing by executing a copy of this letter in the space
provided below, whereupon this letter agreement will become a binding agreement
between FCF and Osiris.

	
  

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Very truly yours,

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FRIEDLI CORPORATE FINANCE, INC.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
  /s/ Peter Friedli

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
  Peter Friedli

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
  President

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AGREED AND ACCEPTED THIS 30th DAY OF OCTOBER, 2006.

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  OSIRIS THERAPEUTICS, INC.

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
  /s/ Cary J. Claiborne

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
  Cary J. Claiborne

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
  Chief Financial Officer

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]